Jerusalem-based Rafa developed the autoinjector through cooperation with the U.S. Department of Defense’s (D0D) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
Rafa’s Midazolam 10mg autoinjector received FDA indication for the treatment of status epilepticus, or prolonged seizures, in adults. This means the new autoinjector can be used to treat seizures resulting from nerve agent exposure. JPEO-CBRND determined that the autoinjector improves upon and will replace the currently fielded convulsant antidote for nerve agent (CANA), the diazepam autoinjector.
Get the full story at our sister site, Drug Delivery Business News.